220 related articles for article (PubMed ID: 18211933)
1. Immunohistochemical localisation of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye.
Peters S; Heiduschka P; Julien S; Bartz-Schmidt KU; Schraermeyer U
Br J Ophthalmol; 2008 Apr; 92(4):541-4. PubMed ID: 18211933
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion.
Julien S; Heiduschka P; Hofmeister S; Schraermeyer U
Br J Ophthalmol; 2008 Oct; 92(10):1424-8. PubMed ID: 18815425
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
Nomoto H; Shiraga F; Kuno N; Kimura E; Fujii S; Shinomiya K; Nugent AK; Hirooka K; Baba T
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
[TBL] [Abstract][Full Text] [Related]
4. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection.
Ishibashi S; Tawara A; Sohma R; Kubota T; Toh N
Arch Ophthalmol; 2010 Dec; 128(12):1539-45. PubMed ID: 21149776
[TBL] [Abstract][Full Text] [Related]
5. Penetration of bevacizumab through the retina after intravitreal injection in the monkey.
Heiduschka P; Fietz H; Hofmeister S; Schultheiss S; Mack AF; Peters S; Ziemssen F; Niggemann B; Julien S; Bartz-Schmidt KU; Schraermeyer U;
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2814-23. PubMed ID: 17525217
[TBL] [Abstract][Full Text] [Related]
6. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.
Peters S; Heiduschka P; Julien S; Ziemssen F; Fietz H; Bartz-Schmidt KU; ; Schraermeyer U
Am J Ophthalmol; 2007 Jun; 143(6):995-1002. PubMed ID: 17449002
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
Miyake T; Sawada O; Kakinoki M; Sawada T; Kawamura H; Ogasawara K; Ohji M
Invest Ophthalmol Vis Sci; 2010 Mar; 51(3):1606-8. PubMed ID: 19875666
[TBL] [Abstract][Full Text] [Related]
8. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
Matsuyama K; Ogata N; Matsuoka M; Wada M; Nishimura T; Takahashi K
J Ocul Pharmacol Ther; 2011 Aug; 27(4):379-83. PubMed ID: 21810018
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model.
Gal-Or O; Dotan A; Dachbash M; Tal K; Nisgav Y; Weinberger D; Ehrlich R; Livnat T
Exp Eye Res; 2016 Apr; 145():412-416. PubMed ID: 26923799
[TBL] [Abstract][Full Text] [Related]
10. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.
Inan UU; Avci B; Kusbeci T; Kaderli B; Avci R; Temel SG
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1773-81. PubMed ID: 17389511
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of intravitreal bevacizumab (Avastin).
Bakri SJ; Snyder MR; Reid JM; Pulido JS; Singh RJ
Ophthalmology; 2007 May; 114(5):855-9. PubMed ID: 17467524
[TBL] [Abstract][Full Text] [Related]
12. Clinical and histological findings after intravitreal injection of bevacizumab (Avastin) in a porcine model of choroidal neovascularization.
Lassota N; Prause JU; Scherfig E; Kiilgaard JF; la Cour M
Acta Ophthalmol; 2010 May; 88(3):300-8. PubMed ID: 19416113
[TBL] [Abstract][Full Text] [Related]
13. Effect of intravitreal injection of high-dose bevacizumab in monkey eyes.
Sakurai K; Akiyama H; Shimoda Y; Yoshida I; Kurabayashi M; Kishi S
Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4905-16. PubMed ID: 19407010
[TBL] [Abstract][Full Text] [Related]
14. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans.
Meyer CH; Krohne TU; Holz FG
Acta Ophthalmol; 2012 Feb; 90(1):68-70. PubMed ID: 20163369
[TBL] [Abstract][Full Text] [Related]
15. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans.
Krohne TU; Eter N; Holz FG; Meyer CH
Am J Ophthalmol; 2008 Oct; 146(4):508-12. PubMed ID: 18635152
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
17. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
Saito Y; Higashide T; Takeda H; Murotani E; Ohkubo S; Sugiyama K
Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
[TBL] [Abstract][Full Text] [Related]
18. Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion.
Chuang LH; Wu WC; Yeung L; Wang NK; Hwang YS; Chen KJ; Kuo JZ; Lai CC
Ophthalmic Res; 2011; 45(1):31-5. PubMed ID: 20714188
[TBL] [Abstract][Full Text] [Related]
19. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
Avisar I; Weinberger D; Kremer I
Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
[TBL] [Abstract][Full Text] [Related]
20. Long-term tolerability and serum concentration of bevacizumab (avastin) when injected in newborn rabbit eyes.
Wu WC; Lai CC; Chen KJ; Chen TL; Wang NK; Hwang YS; Yeung L; Li LM
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3701-8. PubMed ID: 20181842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
